Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2005
03/02/2005CN1586466A Compound dispersion tablet of acetaminophen and benadryl and its preparing method
03/02/2005CN1191362C Streptococcus antigens
03/02/2005CN1191276C Humanized antibodies and method for forming same
03/02/2005CN1191272C Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (VIP)
03/02/2005CN1191266C Compositions for treating inflammatory response
03/02/2005CN1191255C Benzodiazepine derivatives as GABA A receptor modulators
03/02/2005CN1191243C Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
03/02/2005CN1191240C Nitrogen monoxide synthase inhibitor, its preparation method and application
03/02/2005CN1191236C Substituted 6,6-Hetero-dicycloderivative
03/02/2005CN1191233C N-substituted nitrogen heterocyclic compound
03/02/2005CN1191232C Aminomethylcarboxylic acid derivatives
03/02/2005CN1191080C Plaster for treating facial neuritis and its preparing process
03/02/2005CN1191063C Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders
03/02/2005CN1191018C Chewing gum component for eliminating nicotine
03/02/2005CA2479613A1 Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them
03/01/2005US6861529 Cycloalkylpyrrole-3-carboxylic acid amide derivatives and heterocycloalkylpyrrole-3-carboxylic acid amide derivatives that bind with high affinity to the benzodiazepine site of GABA-A (gamma-aminobutyric acid) receptors
03/01/2005US6861525 Reducing the corresponding glyoxylamide compound with phosphorus bormide or chloride
03/01/2005US6861444 Treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; adrenergic blocking agents
03/01/2005US6861443 Drugs; modulator of a nicotinic receptor antagonist
03/01/2005US6861441 (4(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo(f)isoindol-2-yl) phenyl)acetic acid
03/01/2005US6861439 Treatment of cerebrovascular disease
03/01/2005US6861437 Substituted imidazo [1,2-a] pyridine derivatives
03/01/2005US6861434 Dopaminergic neurotransmission modulators
03/01/2005US6861430 β-carboline derivatives and its pharmaceutical use against depression and anxiety
03/01/2005US6861429 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
03/01/2005US6861427 For therapy of cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia, anxiety, aggression and stress, eating disorder, sleep disorder, sexual dysfunction
03/01/2005US6861426 Antiepileptic agents
03/01/2005US6861425 Benzimidazole compounds as ORL1-receptor agonists
03/01/2005US6861421 Nociceptin analogs
03/01/2005US6861420 N-substituted 1,2,4,5-tetrahydro-1H-benzo[d]azepine compounds
03/01/2005US6861417 Such as 2-(4-fluorophenyl)-3-(pyridin-4-yl)pyrazine for treating cytokine mediated diseases such as psoriatic arthritis
03/01/2005US6861399 Cleaning compositions containing human serine protease T
03/01/2005US6861072 Pharmaceutical composition with gastric residence and controlled release
03/01/2005US6861058 Relieving pain related to muscle activity or contracture, antispasmodic
03/01/2005US6861057 Immunogenic β-amyloid peptide
03/01/2005US6861016 Apparatus and method for preparing microparticles
03/01/2005CA2138287C N-substituted azabicycloheptane derivatives, the preparation and use thereof
02/2005
02/24/2005WO2005016928A1 Imidazopyridine derivatives
02/24/2005WO2005016923A1 Novel quinuclidine derivatives and their pharmaceutical use
02/24/2005WO2005016911A1 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
02/24/2005WO2005016901A1 Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
02/24/2005WO2005016900A1 Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
02/24/2005WO2005016898A2 Stable polymorph of bifeprunox mesilate
02/24/2005WO2005016897A1 Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds
02/24/2005WO2005016896A1 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators
02/24/2005WO2005016892A1 Gabanergic modulators
02/24/2005WO2005016891A1 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
02/24/2005WO2005016888A1 Probe for diseases wth amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change
02/24/2005WO2005016884A1 Cyclopropyl derivatives as nk3 receptor antagonists
02/24/2005WO2005016514A2 Combinatorial synthesis on support
02/24/2005WO2005016384A1 Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
02/24/2005WO2005016359A1 Method of promoting remyelination
02/24/2005WO2005016331A1 Therapeutic agent for neuropathic pain containing n-(benzoyl)amino acid derivative as active ingredient
02/24/2005WO2005016327A2 Treatment of sleep disorders with cholinesterase inhibitors
02/24/2005WO2005016325A2 CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
02/24/2005WO2005016228A2 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders
02/24/2005WO2004110492A3 Composition comprising triptans and nsaids
02/24/2005WO2004093789A3 Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
02/24/2005WO2004087195A3 Therapeutic use of modulators of notch and/or kruppel-like factors
02/24/2005WO2004069258A3 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma
02/24/2005WO2004010997A8 Sustained-release tablet composition of pramipexole
02/24/2005WO2003093299A3 Insulin-associated peptides with effects on cerebral health
02/24/2005WO2003018758A3 Reagents and methods for smooth muscle therapies
02/24/2005US20050043536 Sulfonamides
02/24/2005US20050043523 Benzothiazole derivative compounds, compositions and uses
02/24/2005US20050043408 Prevent protein glycation; drug screening; using epinephrine compound
02/24/2005US20050043407 Opioid receptor antagonist and cannabinoid receptor antagonist for treatment of alcohol, cocaine, and/or tobacco dependence
02/24/2005US20050043394 For prophylaxis and therapy of diabetes mellitus, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases, neuropathic diseases, neuropathic pain and polyneuropathy; free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate, deoxyuridine monophosphate
02/24/2005US20050043387 Tricyclic indole compounds having an affinity against serotonin receptors
02/24/2005US20050043386 2-amino-2-(ethyl or methyl)-4-{5-substituted pyrrol-2-yl}butan-1-ols, phosphates and phosphonates; antiarthritic agents; psoriasis; immunosuppressants
02/24/2005US20050043377 Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition
02/24/2005US20050043362 Use of compounds
02/24/2005US20050043355 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
02/24/2005US20050043352 human YAK family of serine/threonine protein kinases (hyak); use treating diseases of the hematopoietic systems, including anemias, polycythemia, myelodysplastic syndrome, myelosuppression, cytopenia, male contraceptives; 2-(3-Chloro-phenylamino)-7-methoxy-quinoline-3-carboxylic acid for example
02/24/2005US20050043350 Administering heterocyclic ether such as 5-chloro-7-hydroxy-3-(4-hydroxyphenylz)-4-oxo-1-benzopyran for prophylaxis of Alzheimer's disease, osteoporosis, cardiovascular disorders, psychological disorders, antiarthritic agents,anxiolytic agents
02/24/2005US20050043348 Phenyl-substituted imidazopyridines
02/24/2005US20050043346 Pyridylpyrrole derivatives active as kinase inhibitors
02/24/2005US20050043341 For stimulation of reverse cholesterol transport, lowering low density lipoproteins in blood; for treatment of hypolipoproteinaemia, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, arteriosclerosis adiposity and obesity stroke or Alzheimer's disease
02/24/2005US20050043340 Process for reacting alkaloids and use of the reaction products in the preparation of medicaments
02/24/2005US20050043337 Selective beta3 adrenergic agonists
02/24/2005US20050043333 Quinazolinone derivative
02/24/2005US20050043332 Such as 4 (cis-3-hydroxycyclopentyl)amino-5,6-dimethyl-2-phenyl-7H-pyrrolo[2,3d] pyrimidine for treatment of adenosine receptor stimulated diseases, cardiovascular disorders, and nervous system disorders
02/24/2005US20050043328 Such as 6-(2-hydroxy-3-chloroxybenzylamino)purine, 6-(2-hydroxy-4-chlorobenzylamino)purine; agriculture; cloning; immunostimulation
02/24/2005US20050043327 Pharmaceutical composition for the prevention and treatment of addiction in a mammal
02/24/2005US20050043324 Polymorphic forms of ziprasidone HCI and processes for their preparation
02/24/2005US20050043316 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same
02/24/2005US20050043314 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
02/24/2005US20050043311 6(5-chloro-2-pyridyl-)-5-[4-methyl-1-piperazinyl]carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine for tranquilizers or hypnotics
02/24/2005US20050043310 Such as (R)-4-bromo-N-[1-(2,4-dichlorophenyl)-ethyl]-2-(quinoxaline-5-quinoxaline-sulfonylamino)-benzamide via sulfonylation; cholecystokinin receptor modulators
02/24/2005US20050043309 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one; use in the treatment of central nervous system disorders, bipolar disorder in a human; chemical synthesis
02/24/2005US20050043305 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof
02/24/2005US20050043303 prophylaxis of cardiovascular disorders comprising administering to mammals inhibitors of cyclic guanosine monophosphate metabolizing phosphodiesterases such as 2-{2-Ethoxy-5-[4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl]-phenyl}-6-methyl-8-propyl-3H-imidazo[1,5-a][1,3,5]triazin-4-one; antiarrythmic agents
02/24/2005US20050043293 Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
02/24/2005US20050043291 Heterocyclic substituted aminoazacycles useful as central nervous system agents
02/24/2005US20050043281 administering for treatment of metabolic bone diseases, mobilizing calcium for osteoporosis, imbalances in the immune system
02/24/2005US20050043269 Pharmaceutically active uridine esters
02/24/2005US20050043242 Using dietary restriction to lower serum insulin levels and function along with troglitazone in treatment and prevention of alzheimer's diseases
02/24/2005US20050043241 Use of inhibitors of given amino acid sequence; inhibit phosphorylation of a transcription factor; can be used to treat or prevent diabetes, ionizing radiation damage, autoimmune diseases, ischemia/reperfusion injuries, heart hypertrophies, cancer
02/24/2005US20050043226 having a building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thioester, or disulfide; used to treat cancers, diabetes, diabetic-associated complications, endocrine disorders, gastrointestinal disorders, and pancreatitis
02/24/2005US20050042738 Carbohydrate-associated proteins
1 ... 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 ... 1833